Guide
How to Check a Tirzepatide Provider in Under Ten Minutes
Five checks against free public databases, each taking under two minutes. The first one ends most conversations: ask which pharmacy fills the prescription. Of thirty prov
Five checks against free public databases, each taking under two minutes. The first one ends most conversations: ask which pharmacy fills the prescription. Of thirty providers in our dataset, one names its fulfilment partners publicly.
What does the comparison actually show?
| Check | Where | Time | What it tells you |
|---|---|---|---|
| 1. Name the pharmacy | State board licensee database | ~90 seconds | If they will not name it, the check ends there |
| 2. 503A or 503B? | Ask the provider | ~30 seconds | Decides your exposure to the bulks proposal |
| 3. FDA warning-letter search | FDA database | ~2 minutes | Search the parent company too, not only the brand |
| 4. Price at 10 mg, in writing | Ask | ~2 minutes | One number means flat; a range means a ladder |
| 5. Refund terms | Ask | ~2 minutes | Including if supply is interrupted |
A named pharmacy can be checked against its state board and against the FDA warning-letter database. An unnamed one cannot be checked at all — not by you, and not by us.
The third check has a trap in it: telehealth brands often trade under a different legal entity, so searching only the consumer brand name produces a false clear. Search the parent company as well.
What none of this establishes: whether a specific vial contains what its label says, or whether sterility practice met USP <797> on the day your batch was made. No desk review reaches those, and a site implying otherwise is overstating what it does.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What did we capture, and where?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How do I know if a tirzepatide provider is legitimate?
Five free checks: name the pharmacy and look it up on the state board, ask whether it is 503A or 503B, search the FDA warning-letter database for the brand and its parent company, get the price at 10 mg in writing, and ask what is refunded.
What if a provider will not name its pharmacy?
Then no external check is possible. Of thirty providers in our dataset, one names its fulfilment partners publicly.
What can no check establish?
Whether a specific vial contains what its label says, or whether sterility practice met USP <797> on the day your batch was compounded.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Cold-Chain Shipping for Compounded GLP-1sPharmacies
- 503B Outsourcing Facility DirectoryPharmacies
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
- 503A Compounding Pharmacy DirectoryPharmacies
- Why Compounded GLP-1 Access Differs by StateJournal
- What PCAB Accreditation MeansPharmacies
Related coverage
GLP-1 Tirzepatide Rank. “How to Check a Tirzepatide Provider in Under Ten Minutes.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/how-to-check-a-tirzepatide-provider-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.